Johnson & Johnson announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma, regardless of transplant status.
Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.
Kite announced findings from three new analyses for Yescarta (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory large B-cell lymphoma, which were presented at 66th American Society of Hematology annual meeting.
Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
Johnson & Johnson announced new frontline data featuring Tecvayli (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma in induction and maintenance settings.
GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma.
Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Johnson & Johnson announced new results from the phase III CARTITUDE-4 study that show a single infusion of Carvykti (ciltacabtagene autoleucel; cilta-cel) significantly increased minimal residual disease negativity rates (10-5) in patients with relapsed or refractory multiple myeloma who were lenalidomide-refractory and had received one to three prior lines of therapy, including a proteasome inhibitor, compared to standard therapies of pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide and dexamethasone.
Smokers with myelodysplastic syndromes or a precursor condition had elevated levels of genetic mutations linked to the disease, a new study shows. The study also found that heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.
